+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Irinotecan HCl Market - Global Forecast 2026-2032- Product Image
Irinotecan HCl Market - Global Forecast 2026-2032- Product Image
Sale

Irinotecan HCl Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6153423
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Irinotecan HCl Market is projected to reach USD 1.22 Billion in 2026. It is expected to continue growing at a CAGR of 7.36%, reaching USD 1.87 Billion by 2032.

Irinotecan HCl: Executive Summary and Strategic Context

Irinotecan hydrochloride (HCl) is a topoisomerase I inhibitor used primarily in oncology, especially in colorectal cancer treatment and selected gastrointestinal, pancreatic, and lung cancer regimens. Its clinical role is shaped by combination protocols, biomarker-informed treatment decisions, toxicity management, and continued integration with targeted and immuno-oncology approaches. Strategic assessment should therefore consider clinical guidelines, regulatory status, hospital procurement, generic competition, and supply reliability rather than product demand alone.

Treatment Pathways Are Shifting Toward Precision and Combination Care

The irinotecan HCl landscape is being transformed by combination treatment, molecular profiling, and more structured toxicity management. Regimens such as FOLFIRI and related protocols require coordinated use of supportive medicines, laboratory monitoring, and dose adjustments, making institutional capability important to treatment access. Pharmacogenomic evidence concerning UGT1A1 variation is also encouraging more individualized evaluation of neutropenia and diarrhea risk, although implementation remains uneven across health systems. At the same time, oral and targeted therapies, antibody combinations, and immunotherapies are changing treatment sequencing and reinforcing the need for evidence-based positioning.

Artificial Intelligence Is Strengthening Selection, Monitoring, and Operations

Artificial intelligence can improve irinotecan HCl delivery by supporting clinical decision-making, adverse-event prediction, treatment scheduling, and supply-chain monitoring. Models trained on electronic health records may help identify patients at elevated risk of severe toxicity, while imaging and molecular-data tools can support response assessment and regimen selection. Natural-language systems can also assist with protocol review and pharmacovigilance signal detection. However, clinical validation, data quality, explainability, privacy protection, and bias controls are essential before AI outputs influence dosing or treatment eligibility. The most credible near-term applications are decision support and operational optimization under clinician oversight.

Regional Differences Reflect Regulation, Oncology Capacity, and Access

North America combines advanced oncology infrastructure, established clinical-trial networks, and strong pharmacovigilance, while reimbursement rules and formulary controls influence product selection. Europe benefits from coordinated guideline development and mature hospital systems, but access and procurement conditions vary across national markets. Asia-Pacific includes sophisticated cancer centers alongside rapidly expanding treatment capacity, with Japan, China, South Korea, and Australia differing in regulatory pathways and clinical practice. Latin America faces uneven availability of oncology services, currency and procurement pressures, and concentration of specialist care. The Middle East shows substantial variation between well-resourced national systems and access-constrained settings. Africa remains highly heterogeneous, with diagnosis delays, specialist shortages, and medicine availability continuing to shape irinotecan HCl use.

Institutional Groups Influence Standards, Procurement, and Access

ASEAN members face differing regulatory maturity, oncology capacity, and dependence on imported medicines, making regional harmonization and resilient distribution valuable. BRICS economies combine large patient populations with varied public-sector procurement systems, domestic manufacturing capabilities, and unequal access to molecular testing. The European Union benefits from shared scientific and regulatory frameworks, although reimbursement and hospital purchasing remain nationally determined. G7 countries generally have strong evidence-generation infrastructure and pharmacovigilance, but cost containment and aging populations remain important considerations. GCC states often possess concentrated, well-funded health systems and are expanding specialist cancer services, while NATO members span diverse healthcare models and can benefit from coordinated resilience planning for critical medicines.

Country Conditions Vary Across Regulation, Capacity, and Clinical Practice

Australia and Canada have publicly oriented systems in which formulary evaluation, regional procurement, and specialist access influence treatment use. Brazil and Mexico face geographic and socioeconomic disparities alongside expanding oncology capabilities. China and India combine growing cancer-care infrastructure with diverse hospital, regulatory, and manufacturing environments. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom maintain established oncology systems, with differences in health technology assessment, reimbursement, prescribing guidance, and hospital purchasing. Russia’s oncology provision is shaped by domestic supply considerations, public procurement, and uneven regional access. The United States has extensive specialist capacity and clinical-trial activity, while payer requirements, site-of-care decisions, and product availability affect treatment pathways.

Prioritize Reliable Supply, Evidence-Based Use, and Toxicity Management

Industry leaders should strengthen quality-assured supply through diversified sourcing, validated manufacturing, inventory visibility, and contingency planning for active ingredients and finished formulations. Clinical value should be demonstrated through guideline-aligned evidence, transparent comparative studies, and practical protocols for managing neutropenia and diarrhea. Organizations should evaluate UGT1A1 testing where clinically and economically appropriate, while avoiding unsupported claims about universal testing. Partnerships with hospitals and professional societies can improve regimen standardization and education. AI investments should begin with auditable decision-support and pharmacovigilance applications, supported by prospective validation, cybersecurity, and clinician governance. Regional strategies should reflect local regulation, reimbursement, laboratory capacity, and procurement realities.

Methodology: Evidence Triangulation Across Clinical and System-Level Sources

This executive summary uses a structured qualitative framework for irinotecan HCl, combining established clinical knowledge with analysis of treatment pathways, regulatory considerations, healthcare-system characteristics, pharmacovigilance priorities, and technology trends. Regional, group, and country comparisons are based on documented differences in oncology capacity, access conditions, procurement structures, and policy environments. Interpretations are restricted to verifiable, generalizable insights and avoid unsupported numerical claims. AI-related observations are framed as potential applications requiring clinical validation rather than as proven outcomes. The assessment should be refreshed against current treatment guidelines, regulatory decisions, supply notifications, and peer-reviewed evidence before operational use.

Conclusion: Resilience and Precision Will Define Irinotecan HCl Strategy

Irinotecan HCl remains an important component of combination oncology care, but its strategic environment is increasingly governed by precision medicine, supportive-care quality, health-system capacity, and supply resilience. Differences across regions, institutional groups, and countries make standardized global assumptions unreliable. Leaders can improve outcomes and operational performance by aligning procurement with continuity planning, embedding toxicity-management expertise, using evidence-based patient selection, and applying AI cautiously under clinical governance. Success will depend on integrating product quality with practical delivery capabilities across the full cancer-care pathway.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of generic Irinotecan HCl biosimilars driving pricing competition across oncology markets
5.2. Increasing use of combination therapies pairing Irinotecan HCl with immunotherapeutic agents in colorectal cancer treatment regimens
5.3. Ongoing clinical trials evaluating novel nanoparticle delivery systems for Irinotecan HCl to reduce toxicity and improve efficacy
5.4. Adoption of pharmacogenomic testing for UGT1A1 polymorphisms to personalize Irinotecan HCl dosing and minimize adverse effects
5.5. Strategic partnerships between pharmaceutical companies and research institutes to accelerate Irinotecan HCl reformulation innovations
5.6. Rising demand for pediatric-friendly Irinotecan HCl formulations addressing off-label pediatric oncology indications
5.7. Regulatory approvals of new Irinotecan HCl combination protocols expanding first-line treatment options in metastatic colorectal cancer
5.8. Market impact of price caps and reimbursement reforms on Irinotecan HCl affordability in emerging economies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Irinotecan HCl Market, by Indication
8.1. Introduction
8.2. Colorectal Cancer
8.3. Lung Cancer
8.4. Pancreatic Cancer
9. Irinotecan HCl Market, by Brand Type
9.1. Introduction
9.2. Brand
9.2.1. Camptosar
9.3. Generic
9.3.1. Cipla
9.3.2. Sandoz
9.3.3. Teva
10. Irinotecan HCl Market, by Formulation
10.1. Introduction
10.2. Lyophilized Powder
10.3. Ready To Use Injection
11. Irinotecan HCl Market, by Dosage Strength
11.1. Introduction
11.2. 100 Mg Vial
11.3. 40 Mg Vial
12. Irinotecan HCl Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Clinics
12.4. Hospitals
12.4.1. Inpatient Department
12.4.2. Outpatient Department
13. Irinotecan HCl Market, by Sales Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.2.1. Inpatient Pharmacy
13.2.2. Outpatient Pharmacy
13.3. Online Pharmacies
13.4. Retail Pharmacies
13.4.1. Chain Pharmacy
13.4.2. Independent Pharmacy
14. Irinotecan HCl Market, by Route Of Administration
14.1. Introduction
14.2. Intravenous Infusion
15. Americas Irinotecan HCl Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Irinotecan HCl Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Irinotecan HCl Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Pfizer Inc.
18.3.2. Teva Pharmaceutical Industries Ltd.
18.3.3. Dr. Reddy's Laboratories Ltd.
18.3.4. Fresenius Kabi AG
18.3.5. Sandoz International GmbH
18.3.6. Sun Pharmaceutical Industries Ltd.
18.3.7. Viatris Inc.
18.3.8. Cipla Limited
18.3.9. Accord Healthcare Limited
18.3.10. Hikma Pharmaceuticals PLC
19. Research AI20. Research Statistics21. Research Contacts22. Research Articles23. Appendix
List of Figures
FIGURE 1. IRINOTECAN HCL MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IRINOTECAN HCL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IRINOTECAN HCL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IRINOTECAN HCL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IRINOTECAN HCL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IRINOTECAN HCL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IRINOTECAN HCL MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. IRINOTECAN HCL MARKET: RESEARCHAI
FIGURE 30. IRINOTECAN HCL MARKET: RESEARCHSTATISTICS
FIGURE 31. IRINOTECAN HCL MARKET: RESEARCHCONTACTS
FIGURE 32. IRINOTECAN HCL MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IRINOTECAN HCL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IRINOTECAN HCL MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IRINOTECAN HCL MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IRINOTECAN HCL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IRINOTECAN HCL MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IRINOTECAN HCL MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IRINOTECAN HCL MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IRINOTECAN HCL MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IRINOTECAN HCL MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IRINOTECAN HCL MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IRINOTECAN HCL MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CAMPTOSAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CAMPTOSAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IRINOTECAN HCL MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IRINOTECAN HCL MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CIPLA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CIPLA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SANDOZ, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SANDOZ, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IRINOTECAN HCL MARKET SIZE, BY TEVA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IRINOTECAN HCL MARKET SIZE, BY TEVA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IRINOTECAN HCL MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IRINOTECAN HCL MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IRINOTECAN HCL MARKET SIZE, BY READY TO USE INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IRINOTECAN HCL MARKET SIZE, BY READY TO USE INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IRINOTECAN HCL MARKET SIZE, BY 100 MG VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IRINOTECAN HCL MARKET SIZE, BY 100 MG VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IRINOTECAN HCL MARKET SIZE, BY 40 MG VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IRINOTECAN HCL MARKET SIZE, BY 40 MG VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IRINOTECAN HCL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IRINOTECAN HCL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INPATIENT DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INPATIENT DEPARTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IRINOTECAN HCL MARKET SIZE, BY OUTPATIENT DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IRINOTECAN HCL MARKET SIZE, BY OUTPATIENT DEPARTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IRINOTECAN HCL MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IRINOTECAN HCL MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IRINOTECAN HCL MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IRINOTECAN HCL MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES IRINOTECAN HCL MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 137. CANADA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 142. CANADA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 143. CANADA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 144. CANADA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 145. CANADA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 146. CANADA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 147. CANADA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. CANADA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. CANADA IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. CANADA IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. CANADA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 152. CANADA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 153. CANADA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. CANADA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. CANADA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 156. CANADA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 157. CANADA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 158. CANADA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 159. CANADA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 166. MEXICO IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 167. MEXICO IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 168. MEXICO IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 169. MEXICO IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 172. MEXICO IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 173. MEXICO IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. MEXICO IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. MEXICO IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. MEXICO IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. MEXICO IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 180. MEXICO IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 181. MEXICO IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 182. MEXICO IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 183. MEXICO IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA IRINOTECAN HCL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. GERMANY IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. GERMANY IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. GERMANY IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 286. GERMANY IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 287. GERMANY IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 288. GERMANY IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 289. GERMANY IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 290. GERMANY IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 291. GERMANY IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 292. GERMANY IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 293. GERMANY IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 294. GERMANY IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 295. GERMANY IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. GERMANY IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. GERMANY IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 298. GERMANY IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 299. GERMANY IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. GERMANY IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. GERMANY IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 302. GERMANY IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 303. GERMANY IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 304. GERMANY IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 305. GERMANY IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. GERMANY IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. FRANCE IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. FRANCE IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. FRANCE IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 310. FRANCE IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 311. FRANCE IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 312. FRANCE IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 313. FRANCE IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 314. FRANCE IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 315. FRANCE IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 316. FRANCE IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 317. FRANCE IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 318. FRANCE IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 319. FRANCE IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. FRANCE IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. FRANCE IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 322. FRANCE IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 323. FRANCE IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. FRANCE IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. FRANCE IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 326. FRANCE IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 327. FRANCE IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 328. FRANCE IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 329. FRANCE IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. FRANCE IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. RUSSIA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. RUSSIA IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. RUSSIA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 334. RUSSIA IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 335. RUSSIA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 336. RUSSIA IRINOTECAN HCL MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 337. RUSSIA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 338. RUSSIA IRINOTECAN HCL MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 339. RUSSIA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 340. RUSSIA IRINOTECAN HCL MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 341. RUSSIA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 342. RUSSIA IRINOTECAN HCL MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 343. RUSSIA IRINOTECAN HCL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 344. RUSSIA IRINOTECAN HCL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 345. RUSSIA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 346. RUSSIA IRINOTECAN HCL MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 347. RUSSIA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. RUSSIA IRINOTECAN HCL MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. RUSSIA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 350. RUSSIA IRINOTECAN HCL MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 351. RUSSIA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 352. RUSSIA IRINOTECAN HCL MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 353. RUSSIA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 354. RUSSIA IRINOTECAN HCL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 355. ITALY IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 356. ITALY IRINOTECAN HCL MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 357. ITALY IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 358. ITALY IRINOTECAN HCL MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 359. ITALY IRINOTECAN HCL MAR

Companies Mentioned

  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceuticals USA, Inc.
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Accord Healthcare
  • Apotex Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Arch Pharmalabs Limited
  • B Joshi Agrochem Pharma
  • BioCare, Inc.
  • CSPC Pharmaceutical Group Limited
  • Fermion Oy
  • Hetero Labs Limited
  • Humble Healthcaare Limited
  • Ipsen Biopharmaceuticals, Inc.
  • Laurus Labs Limited
  • Mac Chem Products (India) Pvt. Ltd.
  • Merck KGaA
  • Olon S.p.A.
  • PV Pharma Healthcare Pvt. Ltd
  • ScinoPharm Taiwan, Ltd.
  • Shanghai Jinhe Bio-Pharma Co., Ltd.
  • Shanghai Trifecta Pharma Co. Ltd.
  • Shilpa Medicare Limited
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Sinoway Industrial Co., Ltd.
  • Tokyo Chemical Industry Co., Ltd.
  • Xi'an Yihui Bio-technology Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

Related Topics

Related Reports

Irinotecan (CAS 97682-44-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Irinotecan (CAS 97682-44-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 65 Pages
  • Global
From
Colorectal Cancer Diagnostics and Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Colorectal Cancer Diagnostics and Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 113 Pages
  • Global
From
Colorectal Cancer Diagnosis and Therapeutic Updates - Product Image

Colorectal Cancer Diagnosis and Therapeutic Updates

  • Book
Colorectal Cancer Therapeutics - Global Strategic Business Report - Product Image

Colorectal Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 883 Pages
  • Global
From
Colorectal Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Colorectal Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.